Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
275 participants
OBSERVATIONAL
2023-10-09
2024-10-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Diverticular disease or diverticulosis is a benign disease of the colon. Diverticulae are pockets of bowel wall which protrude through weaknesses in the muscular wall of the colon. The mechanisms leading to their formation remains unclear and is likely a complex interaction of multiple factors. For the majority of people these pockets are incidental findings they can become inflamed which is called diverticulitis.
The main aim of this study is to see if a faecal samples, which will be tested for hidden blood content with a faecal immunochemical test for haemoglobin (FIT), could be used as an alternative to currently used follow-up investigations for patients who have an episode of acute diverticulitis confirmed on a computerised tomography (CT) scan. These are colonoscopy, sigmoidoscopy or a special CT called CT colonoscopy.
The investigators will also be testing faecal calprotectin which is a marker of bowel inflammation and an assessment of the microbes that live in the bowel to see if this will provide further insights into the diagnosis and treatment of diverticulitis.
Who can participate?
All patients 18 or over admitted to a participating hospital with acute diverticulitis confirmed on a CT scan and who planned to have one of the currently used follow-up investigations are eligible.
What does the study involve?
The study will involve participants taking three stool (faecal) samples using faecal testing kits posted to participants. One is as close to their first solid stool after diagnosis as possible, the others are at 3 weeks after diagnosis and then 6 weeks after diagnosis.
What are the possible benefits and risks of participating?
There are no risks of participating. The investigators hope to demonstrate that a negative FIT test for patients after acute diverticulitis will be able to exclude a bowel cancer and prevent the majority of future patients having invasive and time consuming tests. There no additional benefit for participants for their current episode, as they will still need to have these tests.
Where is the study run from?
Royal Surrey County Hospital
When is the study starting and how long is it expected to run for?
09/10/2023-30/09/2024
Who is funding the study?
The study is being funded by MATTU (Minimal Access Therapy Training Unit), GUTS (GUTS - Fighting Bowel Cancer) and NHIR (National Institute for Health and Care Research).
Who is the main contact?
James Norman, On the study email [email protected]
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Point of Care Faecal Immunochemical Testing for Colorectal Cancer
NCT04402424
Faecal Immunochemical Tests (FIT) for Surveillance After Colorectal Cancer (CRC) Study
NCT06689293
The Diverticulitis Study
NCT06023004
Faecal Immunochemical Test and Urine Volatile Compounds in Adenoma Detection
NCT04146662
Study of Gut Microbiome and Colorectal Tumors
NCT03297996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main aim of this study is to see if a faecal immunochemical test (FIT), could be used as an alternative to currently used follow-up investigations, of colonoscopy, flexible sigmoidoscopy or CT (computerised tomography) colonography, for patients who have an episode of acute diverticulitis to exclude a colorectal cancer (CRC). As stated in the ASCPGBI consensus guidelines 2021 the risk of CRC in those with CT diagnosed uncomplicated diverticulitis is 1.6-1.9% and in those with complicated diverticulitis 7.8-10.9%.
Our primary aim is to determine whether single, or multiple faecal haemoglobin and faecal calprotectin results after an episode of acute diverticulitis can be used to risk stratify for further investigations to exclude colorectal cancer.
Our secondary aims are:
To determine whether single, or multiple faecal haemoglobin and faecal calprotectin results after an episode of acute diverticulitis could be used to risk stratify for further investigations to exclude other colonic findings such as high-risk adenoma?
Would including demographic factors such as age or anaemia allow better risk stratification?
Assess the faecal microbiome in patients with acute diverticulitis and how it changes as inflammation settles.
Any antibiotic treatment will also be recorded and the effect on the faecal microbiome analysed.
Inclusion criteria:
Computerised tomography diagnosis of acute diverticulitis Participants capable of giving informed consent Aged ≥ 18 years Planned for colonoscopy, flexible sigmoidoscopy or CT colonoscopy after diverticulitis diagnosis
Exclusion criteria:
Paediatric patients (\<18 years) Not provided at least 1 FIT sample Unable to/unwilling to provide informed consent Withdrawal of consent for inclusion in study Previous pan-proctocolectomy, subtotal colectomy surgery, or presence of stoma Diagnosed with colorectal cancer Mental health illness limiting compliance Treated in hospital with colonic resection Did not have colonoscopy, flexible sigmoidoscopy or CT colonoscopy
Recruitment:
Patients who attend hospital with a diagnosis of acute diverticulitis confirmed on a CT scan and who have had a clinical decision to follow-up with either a colonoscopy, flexible sigmoidoscopy or CT colonography will be approached for written consent to participate.
Patients will then be posted a patient information leaflet and a pack with collection devices to take samples at home and post back. The results of their follow-up investigation (colonoscopy, flexible sigmoidoscopy or CT colonography + any histology) will be collected when completed
Involvement for patients will involve collecting and posting back in pre-paid envelopes faecal samples on their first solid stool (or as soon as possible after diagnosis) and at 3 and 6 weeks post-diagnosis.
Sample size: 275 - Estimated using available data on diverticulitis and stratified data from FIT use in 2WW patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study cohort
In addition to standard of care, three faecal samples will be obtained. On as soon as possible after diagnosis, one at three weeks post diagnosis and one at six.
Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome
Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome
Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants capable of giving informed consent
* Aged ≥ 18 years
* Clinical decision for colonoscopy, flexible sigmoidoscopy or CT colonoscopy follow-up after diverticulitis diagnosis
Exclusion Criteria
* Not provided at least 1 faecal sample
* Unable to/unwilling to provide informed consent
* Withdrawal of consent for inclusion in study
* Previous pan-proctocolectomy, subtotal colectomy surgery, or presence of stoma
* Currently being treated for colorectal cancer
* Mental health illness limiting compliance
* Treated in hospital with colonic resection
* Did not have colonoscopy, flexible sigmoidoscopy or CT colonoscopy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GUTS - Fighting Bowel Cancer
UNKNOWN
Minimal Access Therapy Training Unit
OTHER
Royal Surrey County Hospital NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sally Benton, FRCPath
Role: STUDY_DIRECTOR
Royal Surrey NHS foundation trust
James Norman, BMBS, MRCP
Role: PRINCIPAL_INVESTIGATOR
Royal Surrey NHS foundation trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Surrey County Hospital
Guildford, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
323724
Identifier Type: OTHER
Identifier Source: secondary_id
55623
Identifier Type: OTHER
Identifier Source: secondary_id
55623
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.